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Evidence for oxidative stress in plasma of patients with Marfan syndrome☆
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G.F. Gensini b,c,d, R. Abbate b,c, G. Pepe b,c
a Department of Biochemical Sciences, University of Florence, Italy
b Department of Medical and Surgical Critical Care, Centre ‘DENOTHE’, University of Florence, Florence, University of Florence, Italy
c Regional Marfan Centre, Azienda Ospedaliera-Universitaria Careggi, University of Florence, Italy
d Centro S. Maria agli Ulivi, Fondazione Don Carlo Gnocchi, Onlus, IRC, Florence, ItalyMarfan syndrome (MFS) is an inherited connective tissue disorder
with multisystemic clinical manifestations subdivided in major and
minor criteria. The presence of twomajor criteria in two organs/systems
and one minor criterion in another allows the diagnosis of MFS [1].
Recently, our groupdescribed the accumulation of oxidationproducts in
fibroblasts from subjects affected by MFS [2]. Although an excess of
reactive oxygen species (ROS) has been invoked as a pathogenetic
mechanism in aortic aneurysm and in othermanifestations occurring in
MFS [3–5] no study, till now, has specifically investigated the occurrence
of oxidative stress in this pathological condition. Thus, we planned to
measure protein carbonyl content (protein CO), accounting for ROS
attackonproteins, and total antioxidant capacity (TAC), an indexof total
ROS scavengers, in the plasma of patients affected by MFS.
We investigated 32 patients (F=13, M=19; median age=34.8 y,
range 13–76 y), diagnosed according to Ghent criteria, who were
referred to the Centre forMarfan Syndrome of the Azienda Ospedaliero-
Universitaria, Careggi, Florence. Selection criteria were age N13 years,
absence of previous aortic intervention, hypertension, diabetesmellitus,
dyslipidemia, renal insufficiency and other major disease states. Thirty
healthy unrelated volunteers (F=13, M=17; median age 36 y, range
15–71 were recruited. None of these subjects was a smoker or was
receiving vitamin supplementation or other drugs. The selection criteria
of controlswere the absence of a family history ofMFS, aortic aneurysm,
sudden death and those previously indicated for Marfan patients.
Clinical score was built up by assigning 2 points to amajor criterion and
1 point to a minor criterion. The authors state that the study protocol
conforms to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institution's human research
committee.
Blood withdrawal was performed after overnight fasting. Plasma
was separated within 1 h and stored at−80 °C until determinations.
TAC was assessed by a chemiluminescence assay [6] using a L-ascorbic
acid standard curve. The levels of protein CO were assessed using 2-4
dinitrophenylhydrazine [7], those of Hcy (free and protein bound)
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Bradford assay [8] .
All experiments were performed in triplicate. Owing to the
symmetry of the distribution, data were summarized as means±SD,
or (for age and Hcy concentrations) as medians (ranges).The statistical
significance of the differences was assessed by the ANOVA-Bonferroni
test, for age and Hcy by the Kruskal–Wallis test. The relationships
between the clinical score and the plasma levels of protein CO and TAC
were analyzed using the Pearson test; for Hcy the same relationships
were analyzed by the Spearman test. A Pb0.05 was accepted as
statistically significant.
In ourMarfan patients cardiovascular systemwas involved in 88% of
cases as a major criterion (28/32) and in 9% as a minor criterion (3/32).
Skeletal and ocular apparatuses were involved as major criteria in 41%
(13/32) and 35% (11/32) of cases, respectively. Positive family history
was present in 75% (24/32) of cases; when considering the minor
criteria, striae distensae (skin) were often present (72%, 23/32), while
pneumothorax was associated to 12% (4/32) of patients, namely dural
ectasia. As only part of the patients agreed to an MRI scan for detecting
dural ectasia, the involvement of CNS was not utilized for scoring. The
distribution of patients on the basis of their clinical score, is shown in
Fig. 1. No significant difference was observed among the median age of
each subgroup of patients.
The results about oxidative stress markers are reported in Fig. 2.
Protein CO was significantly higher in Marfan patients with respect to
controls (0.68±0.20 vs 0.14±0.043 nmol/mg protein), while TAC was
significantly lower (718.9±281.5 vs 1505±400 ascorbate equivalent
units/mg protein). Protein CO values of patients presenting major
involvement of cardiovascular and skeletal apparatuses (0.82±
0.20 nmol/mg protein) or major involvement of cardiovascular and
ocular apparatuses (0.78±0.21 nmol/mg protein) were significantly
higher than those observed in the remaining patients (0.61±0.16 and
0.63±0.18 nmol/mg protein; P=0.02 and P=0.03, respectively). In
any case, the increase in clinical score matched a parallel increase in the
levels of plasma protein CO, and a significant correlation (r=0.85;
Pb0.0001, Fig. 3) was found between these parameters. On the other
hand, neither significant differences nor correlation were found for TAC
values in the same subgroups of subjects (r=0.33; PN0.05).
Plasma Hcy in Marfan patients was moderately, but significantly
(P=0.03), higher (11.6 µmol/L; range 6.2–68.8) than in controls
(10.6 µmol/L; range 6.9–15.2). Hcy levels, however, were correlated
neither with protein CO (r=0.14; P=0.43) nor with TAC values (r=−
0.04; P=0.82).in plasma of patients with Marfan syndrome, Int J Cardiol (2010),
Fig. 1. Pie chart representing the Marfan patients enrolled in this study distinguished on the basis of the assigned Clinical Score: numbers inside and outside the sector arcs indicate
respectively, the median age and the numerousness (as%) of each group.
Fig. 2. Oxidative stress markers in plasma of Marfan patients (n=32) and control
subjects (n=30). TAC is expressed as ascorbate equivalent units/mg protein, protein
CO as nmol/mg protein. For each sample three independent determinations were
performed in triplicate. Values are reported as means±SD. *Significant difference
(Pb0.05) vs control subjects by the ANOVA-Bonferroni test.
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oxidative stress in MFS. Another interesting finding emerging from our
study is thewell-defined and statistically significant positive correlation
between plasma protein CO levels and clinical involvement, thus
suggesting that inMFS the intensity of oxidative stressmay be amarker
of the clinical severity and of the number of organs/systems affected.
TAC levels did not exhibit similar relationships with the clinical
manifestations but, in this regard, it has to be considered that the
antioxidant statusmay be altered by several factors, such as lifestyle andFig. 3. Relationship between the assigned clinical score and the plasma protein CO in the
same patients. Analysis by the Pearson test indicated a good and significant positive
correlationbetween theseoccurrences. Thedashed line indicates the95% confidence interval.
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information in our patients is a limitation of this study.
As for themechanisms responsible for the onset of oxidative stress, it
has been recently demonstrated, in a MFSmouse model [10], a reduced
expression of SOD and an increased expression of iNOS, NAD(P)H
oxidase, and xanthine oxidase that represent themain sources of ROS in
the aortic tissue. Also increased plasma Hcy levels, found in Marfan
patients with major cardiovascular involvement, could enhance ROS
production via NADPH oxidase [11]; in our patients, however, plasma
Hcywasmoderately increased, and no significant correlationwas found
between its levels and thoseof proteinCOorTAC.Ameaningful aspect of
the present study is that the involvement as major criteria of skeletal
and ocular (in addition to cardiovascular) apparatuses was associated
with more marked signs of oxidative stress. This agrees with previous
studies indicating enhanced ROS production in osteopenia and
cataractogenesis [12,13]. Among the factors responsible for the vascular
alterations that characterize MFS (hemodynamic forces, transmural
inflammation, apoptosis and destructive remodelling), activation of
metalloproteinases is thought to play an important role in the
degradation of the extracellular matrix of arterial walls [14]. Most
importantly, ROS have been recently reported to enhance the activation
of TGFbeta 1 [15] whose circulating levels are increased in Marfan
patients [16].
In conclusion the signs of oxidative stress detected in the plasma of
our patients represent a novel finding that strengthens our previous
report about the presence of oxidation products in the fibroblasts of
these patients. Moreover, the significant correlation between the
intensity of oxidative stress and the severity of the clinical manifesta-
tions suggest a systemic oxidative damage, notably that the molecular
pathology of this disorder does not only affect the connective tissue.
Further studies aimed to confirm the presence of oxidative stress
in MFS, to elucidate the mechanisms responsible for its onset and to
assess the pathways of oxidative stress-mediated injury would be of
value, even in a prospect of possible therapeutical interventions.
The authors thank Prof. Vieri Boddi for valuable suggestions and
Daniel Wright for critical reading of the manuscript. The authors state
that the study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki, as reflected in a priori approval by the
institution's human research Committee [17].
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